BIO Announces Presenting Companies for 15th Annual BIO CEO & Investor Conference

• Contact: Abigail Hirsch
• Phone: 202-962-9235
• Email: ahirsch@bio.org

WASHINGTON, D.C. (January 15, 2013) - The Biotechnology Industry Organization (BIO) today announced the initial selection of presenting companies for the 15^thAnnual BIO CEO & Investor Conference to be held February 11-12, 2013 in New York City. All presenting companies are hand-selected for the event, and consist of both private companies and mid-to-large cap established public companies from around the globe. Companies are chosen based on a selection process evaluating a company’s pipeline and R&D activities as well as their focus on biotechnology therapeutics.

“This year’s conference will better accommodate the growing diversity of investors and companies. While the majority of presenting companies at our event are publicly traded, with about half trading with market capitalizations above $100M, for the first time this meeting will also include a unique track that features up to 25 high-caliber and established private company presentations,” said Alan Eisenberg, Executive Vice President of Emerging Companies and Business Development at BIO.  

The following companies are slated to present at this year’s conference:

Private Companies:

• Actinium Pharmaceuticals                            
• ALS Therapy Development Institute
• Aratana Therapeutics                        
• Catabasis Pharmaceuticals       
• CoLucid Pharmaceuticals                   
• Fate Therapeutics                    
• Five Prime Therapeutics                     
• FORMA Therapeutics
• GlobeImmune                                   
• Hydra Biosciences
• Immune Design Corp                        
• KaloBios Pharmaceuticals         
• KineMed                                            
• Kinex Pharmaceuticals  
• Leukemia & Lymphoma Society          
• Mersana   
• The Michael J. Fox Foundation           
• Onconova Therapeutics
• Polynoma                                  
• Promedior                         
• Prosensa Therapeutics                   
• Proteon Therapeutics
• Regado Biosciences                           
• Rib-X Pharmaceuticals
• Sutro Biopharma                               
• Syndax Pharmaceuticals
• Tobira Therapeutics                           
• Trevena
• uniQure                                                                           
• Zafgen

Public Companies:

• Aastrom Biosciences- ASTM                
• ACADIA Pharmaceuticals- ACAD
• Advanced Cell Technology- ACTC
• ADVENTRX Pharmaceuticals- ANX        
• Affymax- AFFY
• Agenus- AGEN                                   
• Alkermes- ALKS
• Alnylam Pharmaceuticals- ALNY           
• Anthera Pharmaceuticals- ANTH                 
• Antisense Therapeutics– ASX:ANP             
• Apricus Biosciences- APRI                               
• Aradigm Corporation- ARDM                
• Arena Pharmaceuticals- ARNA                      
• Astex Pharmaceuticals- ASTX                   
• Athersys- ATHX
• Atossa Genetics- ATOS                           
• Biodel- BIOD
• BioDelivery Sciences International- BDSI
• BioLineRx– BLRX                                   
• BioMarin- BMRN                                
• Biotie Therapies– HEL:BTH1V
• Catalyst Pharmaceuticals Partners- CPRX      
• Celgene Corporation- CELG
• CEL-SCI Corporation- CVM                  
• Cempra- CEMP
• ChemoCentryx- CCXI                         
• Cleveland BioLabs- CBLI             
• Curis- CRIS
• Cyclacel Pharmaceuticals- CYCC                       
• Cytokinetics- CYTK
• CytRx Corporation- CYTR                    
• DARA BioSciences- DARA                     
• DiaMedica– CVE:DMA
• DURECT Corporation- DRRX
• Eli Lilly - LLY                                             
• EpiCept Corporation- EPCT
• Eternity Healthcare- ETAH
• Exelixis- EXEL                                             
• Furiex Pharmaceuticals- FURX
• Galena BioPharma - GALE                                  
• GENFIT– EPA:ALGFT
• GenVec- GNVC                    
• GeoVax Labs- GOVX
• Gilead Sciences- GILD
• GTx - GTXI     
• Horizon Pharma- HZNP
• Hyperion Therapeutics - HPTX              
• iCo Therapeutics– CVE:ICO
• Idenix Pharmaceuticals - IDIX
• Idera Pharmaceuticals- IDRA
• ImmunoCellular Therapeutics- IMUC
• ImmunoGen- IMGN
• Immunovaccine – CVE:IMV                              
• Inovio Pharmaceuticals  - INO
• Intercept Pharmaceuticals- ICPT
• Lexicon Pharmaceuticals - LXRX           
• MDx Health– EBR:MDXH
• NanoViricides- NNVC
• Navidea - NAVB
• NeoStem- NBS
• Neuralstem- CUR
• Newron Pharmaceuticals– NWRN-CH
• NicOx– EPA:COX           
• NovaBay Pharmaceuticals- NBY
• Novavax - NVAX
• Novelos Therapeutics- NVLT
• NPS Pharmaceuticals - NPSP
• Nymox Pharmaceutical Corporation- NYMX
• Oculus Innovative Sciences- OCLS
• Ohr Pharmaceutical- OHRP
• OncoGenex Pharmaceuticals- OGXI
• Oncolytics Biotech – TSE:ONC                           
• OncoSec Medical– ONCS
• Onyx Pharmaceuticals- ONXX
• Opexa Therapeutics - OPXA               
• Oragenics- OGEN
• Orexigen - OREX                        
• OXiGENE- OXGN
• Palatin Technologies - PTN         
• PDL BioPharma- PDLI
• Pozen- POZN
• Prima Biomed– ASX:PRR
• ProMetic Life Sciences – TSE:PLI                
• Protalix BioTherapeutics - PLX   
• Provectus Pharmaceuticals  - PVCT
• pSiVida Corp - PSDV                             
• Q Therapeutics
• Regulus Therapeutics- RGLS
• ReNeuron– LON:RENE
• Repros Therapeutics- RPRX
• Resverlogix – TSE:RVX   
• Rigel Pharmaceuticals- RIGL
• RXi Pharmaceuticals - RXII                 
• SciClone Pharmaceuticals- SCLN
• Soligenix - SNGX     
• Stallergenes– EPA:GENP
• StemCells- STEM
• Sucampo Pharmaceuticals- SCMP
• Synthetic Biologics- SYN
• Targacept - TRGT       
• Tekmira Pharmaceuticals Corp– TSE:TKM
• Tengion - TNGN
• TG Therapeutics- TGTX
• TiGenix – EBR:TIG            
• Tonix Pharmaceuticals- TNXP
• Transcept Pharmaceuticals- TSPT
• Transition Therapeutics– TSE:TTH     
• Tranzyme- TZYM
• TrovaGene- TROV                                 
• Venaxis- APPY
• Verastem- VSTM
• VirtualScopics- VSCP
• Zalicus- ZLCS
• Zealand Pharma - ZEAL
• ZIOPHARM Oncology- ZIOP

Check back often as new presenters are continuously being added. Companies interested in presenting their story can submit an application at http://www.bio.org/events/conferences/bio-ceo-application-present.

About BIO CEO & Investor Conference

The BIO CEO & Investor Conference is the largest investor conference focused on publicly traded biotech companies. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

The BIO CEO & Investor Conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.

BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors including supporting banks Stifel Nicolaus Weisel, Leerink Swann and ROTH Capital Partners, LLC.

###